NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Infectious Disease Nucleic Acid Testing
http://www.reportlinker.com/p0591342/Infectious-Disease-Nucleic-Acid-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products.
Contains 360 pages and 20 tables
Table of Contents
1. Overview
2. Major Infectious Diseases
AIDS
Structure and Composition
Classification
AIDS Origins
Animal Lentivirus Systems
Virus Receptors
HIV Infections in Humans
Pathogenesis and Pathology
CD4T Lymphocytes and Memory Cells
Monocytes and Macrophages
Lymphoid Organs
Neural Cells
Viral Coinfections
Clinical Findings
Plasma Viral Load
Pediatric AIDS
Neurologic Disease
Opportunistic Infections
Cancer
Immunity
Laboratory Diagnosis
Virus Isolation
Serology
Viral Nucleic Acid/Antigen Detection
Epidemiology
Worldwide Spread of AIDS
United States
Routes of Transmission
Prevention, Treatment, And Control
Antiviral Drugs
Vaccines
Transmission HIV in Blood Products
HIV Transmission in Transplant and Artificial Insemination Recipients
Diagnostic Tests
Enzyme Immunoassay Interpretation
Specificity, Sensitivity and Predictive
Value
Competition Assays
Western Blot Technique
ImmunoFluorescence Assays (IFA)
Radioimmunoprecipitation
HIV1/HIV2 Combination Testing
Methods of HIVAntigen Detection
Antigen Assays and Blood Screening
Urine Tests
DNA Probes
Overview
Quantitative PCR
In Situ PCR
Needed Improvements
Viral Load/Drug Resistance Testing
Genotype and Phenotype Testing
Blood Banking Considerations
Adenovirus
Background
Diagnostic Tests
Vaccines and Drugs
AdenoAssociated Viruses (AAV)
Anthrax/Bacillus Anthracis
Background
Diagnostic Tests
Vaccines and Drugs
Babesiosis
Background
BEA and Other Bartonella Diseases
Background
Diagnostic Tests
Vaccines and Drugs
Chagas Disease
Background
Campylobacter
Background
Diagnostic Tests
Culture Identification
Vaccines and Drugs
Chlamydia
Background
Chlamydia psittaci
Chlmaydia pneumoniae
Chlamydia trachomatis
Diagnostic Tests
Vaccines and Drugs
CreutzfeldtJakob's Disease
Background
Blood Transmission
Diagnostic Tests
Major Commercial and Academic Players
Bayer
Disease Sciences/Bio Tec Global
Imperial College School of Medicine
OrthoClinical Diagnostics
Pall
ProMetic Life Sciences
Proteome Sciences/Idexx
QOne Biotech
Serono
U.S. Agricultural Research Service
Drugs
Vaccines
Cytomegalovirus
Background
Chorioretinitis
Gastrointestinal
Central Nervous System Disease
Diagnostic Tests
Vaccines and Drugs
Ebola Virus
Background
Epidemiology
Clinical Syndromes
Diagnostic Tests
Vaccines and Drugs
EchoVirus
Background
Acute Aseptic Meningitisis
Encephalitis
Exanthems
Respiratory Disease
Myopericarditis
Neonatal Infections
Diagnostic Tests
Vaccines and Drugs
Encephalitis
Background
Diagnostic Tests
Vaccines and Drugs
Enteroviruses
Background
Diagnostic Tests
Viral Isolation and Identification
Antibody Tests
Vaccines and Drugs
EpsteinBarr Virus
Background
Diagnostic Tests
Vaccines and Drugs
Gonorrhea
Background
Diagnostic Tests
Vaccines and Drugs
Hepatitis
Hepatitis A
Hepatitis B
Structure and Composition
Replication
Hepatitis C
Hepatitis D (Delta)
Hepatitis E
Hepatitis G
Hepatitis Infections Pathology
Clinical Findings
Laboratory Tests
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
VirusHost Immune Reactions
Epidemiology
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D (Delta)
Vaccines and Drugs
Herpes Simplex Virus
Background
Diagnostic Tests
Vaccines and Drugs
Legionella
Background
Diagnostic Tests
Vaccines and Drugs
Lyme Disease
Background
Clinical Description
Clinical Case Definition
Laboratory Criteria for Diagnosis
Case Classification
Diagnostic Tests
Vaccines and Drugs
Malaria
Mycoplasma
Background
Ureaplasma Urealyticum & Mycoplasma
Hominis
Diagnostic Tests
Vaccines and Drugs
Papillomaviruses/HPV
Background
HPV in Cancer
Cervical Neoplasm
Diagnostic Tests
Vaccines and Drugs
Prevention
Parvovirus B19
Background
Microbiology
Epidemiology
Clinical Syndromes
Erythema Infectiosum (Slapped Cheek)
Adult Polyarthropathy
Transient Aplastic Crisis
Transient Pancytopenia
Red Cell Aplasia in Immunocompromised
Perinatal Infections
Diagnostic Test
Vaccines and Drugs
Pneumonia
Background
Diagnostic Tests
Vaccines and Drugs
Polyomaviruses
Background
Diagnostic Tests
Vaccines and Drugs
Salmonellosis
Background
Diagnostic Tests
Vaccines and Drugs
Shigellosis
Background
Diagnostic Tests
Vaccines and Drugs
Streptococci
Background
Diagnostic Tests
Vaccines and Drugs
Group A Streptococci
Group B Streptococci
Toxoplasmosis
Background
Diagnostic Tests
Vaccines and Drugs
Tuberculosis
Background
Diagnostic Tests
Microscopic Characteristics
Cultural Characteristics
Skin Tests
MDRTB
Vaccines and Drugs
West Nile Virus
Background
Clinical Syndromes
Diagnostic Tests
Vaccines and Drugs
Yersinia
Background
Diagnostic Tests
Vaccines and Drugs
3. Antibiotic Susceptibility
List of Tables
Table 1: Major Companies Developing or Marketing AIDS NAT and other Direct Identification Tests
Table 2: Major Companies Developing or Marketing Adenovirus NAT and other Direct Identification Tests
Table 3: Major Companies Developing or Marketing Campylobacter NAT and ther Direct Identification Tests
Table 4: Major Companies Developing or Marketing Chlamydia NAT and other Direct Identification Tests
Table 5: Major Companies Developing or Marketing CMV NAT and other Direct Identification Tests
Table 6: Major Companies Developing or Marketing EBV NAT and other Direct Identification Tests
Table 7: Major Companies Developing or Marketing Gonorrhea NAT and other Direct Identification Tests
Table 8: Major Companies Developing or Marketing Hepatitis NAT and other Direct Identification Tests
Table 9: Major Companies Developing or Marketing Herpes NAT and other Direct Identification Tests
Table 10: Major Companies Developing or Marketing Legionella NAT and other Direct Identification Tests
Table 11: Major Companies Developing or Marketing Lyme Disease NAT and ther Direct Identification Tests
Table 12: Major Companies Developing or Marketing Mycoplasma NAT and other Direct Identification Tests
Table 13: Major Companies Developing or Marketing Papilloma Virus NAT and ther Direct Identification Tests
Table 14: Major Companies Developing or Marketing Pneumonia NAT and other Direct Identification Tests
Table 15: Major Companies Developing or Marketing Salmonella NAT and other Direct Identification Tests
Table 16: Major Companies Developing or Marketing Shigella NAT and other Direct Identification Tests
Table 17: Major Companies Developing or Marketing Streptococci NAT and ther Direct Identification Tests
Table 18: Major Companies Developing or Marketing Toxoplasmosis NAT and ther Direct Identification Tests
Table 19: Major Companies Developing or Marketing Tuberculosis NAT and ther Direct Identification Tests
Table 20: Major Companies Developing or Marketing Cancer NAT Tests
Table 21: Major Companies Developing or Marketing NAT Test for Genetic Diseases
To order this report:
In Vitro Diagnostic Industry: Infectious Disease Nucleic Acid Testing
In Vitro Diagnostic Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article